Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)

Recruiting now · Phase 3

Conditions studied: Acute Decompensated Heart Failure

In brief

The objective of this study is to prospectively compare decongestive therapy administered by the Reprieve System to Optimal Diuretic Therapy (ODT) in the treatment of patients diagnosed with acute decompensated heart failure (ADHF). The main objective is to determine if the Reprieve System can more efficiently decongest ADHF patients in comparison to Control Therapy.

Key facts

Study ID

NCT06898515

Run by

Reprieve Cardiovascular, Inc

People needed

400

Starts

2025-07-14

Expected to finish

2027-12-01

Last updated by the study team

2025-11-26

Who can join

Age: 22 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of HF with expected hospitalization >24 hours, with >1 new or worsening symptom and >2 physical examination, laboratory, or invasive findings of HF, and receiving or with plans to receive a HF-specific treatment
• ≥10 lb. (4.5 kg) above dry weight as estimated by health care provider.
• Current outpatient prescription for daily loop diuretic.
• Participants ≥ 22 years of age able to provide informed consent and comply with study procedures.
• Elevated risk of diuretic resistance, as indicated by at least one of the following: Baseline hypochloremia OR Urine output <1L in the 6 hours following IV loop diuretic >=40 mg furosemide equivalent OR Spot urine sodium <100 mmol/L 1-2 hours after IV loop diuretic >= 40 mg furosemide equivalent

You may not qualify if…

• Urologic issues that would predispose the participant to a high rate of urogenital trauma or infection with catheter placement or known inability to place a Foley catheter.
• Hemodynamic instability as defined by any of the following: sustained systolic blood pressure <90 mmHg for >15 minutes within the past 48 hours, use of IV vasopressors or inotropes within past 48 hours, and/or current or previous mechanical circulatory support within the last week.
• Uncontrolled arrhythmias defined as sustained HR >130 beats/min for >10 minutes within the past 48 hours.
• Severe lung disease with chronic home oxygen requirement >2L/min.
• Acute infection with evidence of systemic involvement (e.g., clinically suspected infection with fever or elevated serum white blood cell count).
• Estimated glomerular filtration rate (eGFR) <25 ml/min/1.73m2 (calculated with either MDRD or CKD-EPI) or current use of renal replacement therapy (RRT).
• Significant left ventricular outflow obstruction, severe uncorrected complex congenital heart disease, known severe stenotic valvular disease, severe infiltrative or constrictive cardiomyopathy or other diagnosis that would make aggressive decongestion unsafe.
• Current or recent (< 30 days) type I myocardial infarction (e.g., acute coronary syndrome such as NSTEMI or STEMI from plaque rupture), coronary artery bypass surgery, or stroke. An isolated troponin elevation (e.g., from volume overload or demand ischemia) is not a reason for exclusion.
• Severe electrolyte abnormalities (e.g., serum potassium <3.0 mEq/L, magnesium <1.3 mEq/L or sodium <125 mEq/L). Note: These are based on baseline/screening labs. Participants whose electrolyte levels are repleted cannot be reassessed for inclusion in the trial.
• Other concomitant disease or condition the investigator believes will make it difficult to follow instructions or comply with study procedures and/or follow-up visits, including expected prolonged hospitalization for reasons other than decongestive therapy
• Currently enrolled in an interventional trial (observational studies are permitted).
• Life expectancy less than 6 months.
• Women who are pregnant or breastfeeding.

Where it is running

• Prisma Health Greenville Memorial Hospital — Greenville, South Carolina, United States (enrolling)
• UC Davis Medical Center — Sacramento, California, United States (enrolling)
• UH Cleveland Medical Center — Cleveland, Ohio, United States (enrolling)
• University of Pennsylvania — Philadelphia, Pennsylvania, United States (enrolling)
• Piedmont Augusta Hospital — Augusta, Georgia, United States (enrolling)
• Northeast Georgia Medical Center — Gainesville, Georgia, United States (enrolling)
• University of California Irvine — Irvine, California, United States (enrolling)
• University of Kansas Medical Center — Kansas City, Kansas, United States (enrolling)
• Ohio State University Hospital — Columbus, Ohio, United States (enrolling)
• Oklahoma Heart Hospital — Oklahoma City, Oklahoma, United States (enrolling)
• Corewell Health Butterworth Hospital — Grand Rapids, Michigan, United States (enrolling)
• Corewell William Beaumont University Hospital — Royal Oak, Michigan, United States (enrolling)
• Minneapolis Heart Institute — Minneapolis, Minnesota, United States (enrolling)
• University of Mississippi — Jackson, Mississippi, United States (enrolling)
• University of Florida — Gainesville, Florida, United States (enrolling)
• St. Louis VA — St Louis, Missouri, United States (enrolling)
• Washington University — St Louis, Missouri, United States (enrolling)
• University of Nebraska Medical Center — Omaha, Nebraska, United States (enrolling)
• Stony Brook University Hospital — Stony Brook, New York, United States (enrolling)
• Piedmont Atlanta Hospital — Atlanta, Georgia, United States (enrolling)
• Trinity Health Ann Arbor Hospital — Ann Arbor, Michigan, United States (enrolling)
• Atrium Health Wake Forest Baptist Medical Center — Winston-Salem, North Carolina, United States (enrolling)
• Lindner Center at Christ Hospital — Cincinnati, Ohio, United States (enrolling)
• University of Cincinnati — Cincinnati, Ohio, United States (enrolling)
• Baylor Scott and White — Dallas, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.